AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback